Norway Country Drug Report 2019

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

There were no associated comprehensive budgets for the Norwegian National Action Plan on Alcohol and Drugs (2007-12); however, the government estimated that, between 2007 and 2011, approximately EUR 125 million of public funds was allocated to drug-related activities. Neither the method nor the data used to calculate this estimate could be assessed.

In the action plan for 2016-20, a budget of EUR 252 million (NOK 2.4 billion) was allocated to the drugs and alcohol field. In 2016 and 2017, the grant was increased by EUR 56 million (NOK 541 million) and EUR 46 million (NOK 446 million), respectively. In addition, around EUR 16 million (NOK 150 million) has been budgeted for interdisciplinary specialised treatment for illicit drugs and alcohol use in 2018.

Over the last decade, because of the decentralised health and social service systems in Norway, a large number of authorities, institutions and organisations have been involved in drug policy funding. The total size of and trends in drug-related public expenditure have not been estimated.

Norway main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.